In MM, BIRC5 expression, detectable in 43% of myeloma cell samples, is associated with proliferation, prognostically adverse chromosomal aberrations (del17p and gain of 1q21), and gene expression based high-risk scores. This evidence concerns the gene BIRC5 and plasma cell myeloma.